Stockreport

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney [Read more]